Exact Sciences UK, Ltd.
Getting ahead of cancer is crucial no matter where people are in their cancer journey. From earlier cancer detection to treatment guidance and monitoring, we are helping people get the answers they need to make more informed decisions across the cancer continuum. With a leading portfolio of products for earlier detection and treatment guidance, we help people face the most challenging decisions with confidence. Our dedication to taking on the impossible fuels everything we do. We are continuously innovating, combining scientific rigor with an open-minded approach to deliver the next big thing.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Clinical Services
- Market Focus:
- Globally (various continents)
About Us
PURSUING EARLIER DETECTION AND LIFE-CHANGING ANSWERS
From earlier cancer detection to treatment guidance and monitoring, Exact Sciences is helping people face their most challenging decisions with confidence.
PROVIDING EARLIER, SMARTER ANSWERS
We understand the role we play in the fight against cancer. From earlier cancer detection through treatment guidance and monitoring, we're working to enable patients and providers to take action sooner—when it matters most.
DELIVERING LIFE-CHANGING INNOVATIONS
We are relentless in our pursuit to find the right science and technology for every challenge. Our approach is defined not only by our thorough process, but also by our willingness to explore any angle that leads to the best answer.
KEEPING PEOPLE FIRST
The most effective and revolutionary solutions start with a focus on people. The empathetic spirit that fuels our culture drives us to create and deliver solutions rooted in the needs of patients, providers, and families.
The Pipeline
The Exact Sciences’ pipeline is expanding at a rapid pace. We’re taking the same innovative problem-solving approach that resulted in the multitarget stool DNA test (Cologuard®) to tackle a wide array of cancer screening challenges. We’re also leveraging the success and impact of the Oncotype DX® portfolio of tests to transform patient treatment decisions. Through our pipeline efforts, we aim to give patients and clinicians confidence, while helping to provide smart answers at every step of the cancer journey.
How We're Achieving This Ambitious Goal:
- Building a cancer detection platform upon learnings from the development of the Cologuard test
- Expanding the Oncotype DX platform to include liquid and tissue-based tests, all with the goal of making cancer care smarter
- Adapting biomarker-based technologies to create a liquid biopsy capable of detecting cancers and precancers from a blood sample
- Using our proven multimarker approach to achieve analytical sensitivity needed to discriminate between normal and cancerous samples
- Collaborating with world-class clinicians and scientists at Mayo Clinic to identify biomarkers associated with the 15 deadliest cancers